Domainex Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Domainex Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014044
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Domainex Ltd (Domainex) is a biotechnology company that provides drug discovery technologies and services. The company offers drug discovery services in the areas of medicinal chemistry, computational chemistry, protein expression and purification, biochemical assay development, DMPK analysis, cell biology, combinatorial domain hunting, and hit identification using virtual or fragment-based approaches. It provides methyltransferases and solutions for the treatment of novel treatment for inflammatory diseases such as DMXD-011, a small-molecule orally-bio available inhibitor for rheumatoid arthritis and lupus. Domainex develops a range of drug target classes which include kinases, proteases, ion channels, proteins involved in epigenetics and protein-protein interactions. The company provides discovery technology platform such as combinatorial domain hunting and fragment-based screening. It develops therapies for oncology and autoimmune diseases. Domainex is headquartered in Saffron Walden, the UK.

Domainex Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Domainex Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Domainex Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Domainex Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Domainex Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Domainex Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Domainex Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Domainex Raises Funds In First Tranche Of US$2.3 Million Venture Financing Round 10
Partnerships 11
Domainex Expands its Agreement with Imperial College London 11
ZoBio and Domainex Enter into Agreement with Forma Therapeutics 12
Domainex Extends Co-Development Agreement with Auspherix 13
Horizon Discovery Enters Into Agreement With Domainex To Support Oncology Program 14
Domainex Ltd – Key Competitors 15
Domainex Ltd – Key Employees 16
Domainex Ltd – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Corporate Communications 18
Mar 30, 2017: Domainex appoints Timo Veromaa as Executive Chairman 18
Product News 19
04/26/2016: Queen’s University Belfast and Domainex Win Late-Stage Award to Progress Novel Lung Cancer Drug Candidate into the Clinic 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
Domainex Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Domainex Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Domainex Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Domainex Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Domainex Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Domainex Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Domainex Raises Funds In First Tranche Of US$2.3 Million Venture Financing Round 10
Domainex Expands its Agreement with Imperial College London 11
ZoBio and Domainex Enter into Agreement with Forma Therapeutics 12
Domainex Extends Co-Development Agreement with Auspherix 13
Horizon Discovery Enters Into Agreement With Domainex To Support Oncology Program 14
Domainex Ltd, Key Competitors 15
Domainex Ltd, Key Employees 16

★海外企業調査レポート[Domainex Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Harvard Stem Cell Institute-製薬・医療分野:企業M&A・提携分析
    Summary Harvard Stem Cell Institute (HSCI), a subsidiary of Harvard University is a healthcare institute that conducts research on advance stem cell science using stem cell biology to develop new treatments and cures for disease. The institute provides research programs such as disease programs, cor …
  • Lysogene SAS (LYS):製薬・医療:M&Aディール及び事業提携情報
    Summary Lysogene SAS (Lysogene) is a clinical research center that offers basic research and clinical development programs. The center offers clinical development of gene therapy for neurodegenerative disorders such as Parkinson and Alzheimer diseases. It also develops models in gene therapy trials …
  • Harvard Stem Cell Institute:製薬・医療:M&Aディール及び事業提携情報
    Summary Harvard Stem Cell Institute (HSCI) a subsidiary of Harvard University is a healthcare institute that conducts research on advance stem cell science using stem cell biology to develop new treatments and cures for disease. The institute provides research programs such as disease programs, core …
  • S&P Global Inc (SPGI):企業の財務・戦略的SWOT分析
    S&P Global Inc (SPGI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Repower AG:電力:M&Aディール及び事業提携情報
    Summary Repower AG (Repower), formerly Ratia Energie AG is an energy company that produces, transmits and distributes electricity. The company's services include trading, market access, and sales support services. It generates electric energy from hydropower, wind power plants, and combined-cycle ga …
  • Double Bond Pharmaceutical International AB (DBPB):製薬・医療:M&Aディール及び事業提携情報
    Summary Double Bond Pharmaceutical International AB (DBP) is a pharmaceutical company that design, develop and commercialize therapies for cancer and autoimmune diseases. The company’s product pipeline includes SI-053 (Temodex), a novel therapy to treat malignant brain tumors; SA-033, SA-042, and SA …
  • Kamada Ltd (KMDA):企業の財務・戦略的SWOT分析
    Kamada Ltd (KMDA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Vermilion Energy Inc (VET):石油・ガス:M&Aディール及び事業提携情報
    Summary Vermilion Energy Inc (Vermilion) is an oil and gas company that offers exploration and production services. The company is an oil and gas producer in Alberta. It offers production programs focusing on acquisition, exploration, development and optimization in North America, Europe and Austral …
  • Companhia Riograndense de Mineracao:企業の戦略・SWOT・財務分析
    Companhia Riograndense de Mineracao - Strategy, SWOT and Corporate Finance Report Summary Companhia Riograndense de Mineracao - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Wolverine Power Supply Cooperative Inc:企業の戦略的SWOT分析
    Wolverine Power Supply Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and ma …
  • Linamar Corporation:企業の戦略・SWOT・財務分析
    Linamar Corporation - Strategy, SWOT and Corporate Finance Report Summary Linamar Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Brinker International, Inc.:企業の戦略・SWOT・財務分析
    Brinker International, Inc. - Strategy, SWOT and Corporate Finance Report Summary Brinker International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Synthon Holdings BV:企業の戦略的SWOT分析
    Synthon Holdings BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • WABCO Holdings Inc.:戦略・SWOT・企業財務分析
    WABCO Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary WABCO Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Rodin Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Rodin Therapeutics Inc (Rodin Therapeutics) discovers and develops novel medicines targeting epigenetics and novel chemical strategies for cognitive impairment of neurological and neuropsychiatric disorders. Its translational therapeutic strategy harnesses the power of epigenetic regulation …
  • CUNA Mutual Group:企業の戦略・SWOT・財務情報
    CUNA Mutual Group - Strategy, SWOT and Corporate Finance Report Summary CUNA Mutual Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Newalta Corp (NAL):石油・ガス:M&Aディール及び事業提携情報
    Summary Newalta Corp (Newalta) is a provider of sustainability-enhancing solutions to the oil and gas industry. It adopts technologies to maximize the value inherent in oil and gas exploration and production waste streams. The company provides engineered environmental solutions for waste management …
  • Inventiva (IVA)-製薬・医療分野:企業M&A・提携分析
    Summary Inventiva is a drug discovery company that endeavors to develop breakthrough therapies for cancer, fibrosis and rare diseases. The company’s product pipeline includes IVA336 for mucopolysaccharidosis type VI (MPS VI) and IVA337 for systemic sclerosis. Inventiva develops a novel internal canc …
  • Kaiser Permanente:企業の戦略・SWOT・財務分析
    Kaiser Permanente - Strategy, SWOT and Corporate Finance Report Summary Kaiser Permanente - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • PetSmart, Inc.:企業の戦略・SWOT・財務情報
    PetSmart, Inc. - Strategy, SWOT and Corporate Finance Report Summary PetSmart, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆